STOCK TITAN

NeuBase Therapeutics Inc - NBSE STOCK NEWS

Welcome to our dedicated news page for NeuBase Therapeutics (Ticker: NBSE), a resource for investors and traders seeking the latest updates and insights on NeuBase Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect NeuBase Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of NeuBase Therapeutics's position in the market.

Rhea-AI Summary
NeuBase Therapeutics, Inc. (NBSE) received a notice from Nasdaq regarding non-compliance with listing requirements due to a delayed Annual Report filing. The company has until June 3, 2024, to submit a compliance plan and potentially until September 30, 2024, to regain compliance.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.77%
Tags
none
-
Rhea-AI Summary
NeuBase Therapeutics responds to Symetryx Corporation's request for a special dividend of $1 per share
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-16.04%
Tags
none
-
Rhea-AI Summary
Symetryx Corporation has acquired 20% of the common stock in Neubase Therapeutics and is urging the Board to issue a special $1 per share dividend. Symetryx believes that Neubase's cash position makes it an attractive merger candidate and that a dividend would not make the company less attractive. Symetryx is also open to exploring other options such as a merger, acquisition, or winding down of the company.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
106.96%
Tags
Rhea-AI Summary
NeuBase halts development of programs and explores strategic alternatives to maximize shareholder value.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-20.49%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.76%
Tags
none
Rhea-AI Summary
NeuBase Therapeutics has entered into definitive agreements for the issuance and sale of shares of common stock and warrants in a registered direct offering and private placement. The offerings are expected to raise approximately $5 million in gross proceeds, which will be used for working capital and general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.11%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-16.67%
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.12%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.99%
Tags
NeuBase Therapeutics Inc

Nasdaq:NBSE

NBSE Rankings

NBSE Stock Data

1.65M
3.30M
13.38%
12.68%
4%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Pittsburgh

About NBSE

neubase has developed a modular antisense technology platform with the capability to address any rare genetic disease caused by mutant proteins with a single, cohesive approach. neubase's platform improves upon gene silencing therapies by combining the advantages of synthetic approaches with the precision of antisense technologies. neubase plans to use its unparalleled antisense platform to address both repeat expansion disorders, with an initial focus on huntington's disease and myotonic dystrophy, and dominant genetic disorders.